Skip to content

Study · Non-randomized trial · n = 101 · 2000

5 results

Sustained improvements in patients with dementia of Alzheimer's type (DAT) 6 months after termination of Cerebrolysin therapy.

Rüther E, Ritter R, Apecechea M, Freytag S, Gmeinbauer R, Windisch M

Journal of neural transmission (Vienna, Austria : 1996)1 Jan 2000Cited by 34 (Europe PMC)

PMID11005546 (opens in a new tab)DOI10.1007/s007020070061 (opens in a new tab)PepBankPUB-11005546
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with Alzheimer's-type dementia, Cerebrolysin largely maintained CGI improvement during follow-up compared with placebo.

    In plain wordsIn patients with dementia, Cerebrolysin largely maintained global clinical improvement during follow-up compared with placebo.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseGlobal rating CGI at follow-up
    Study

    n = 101

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    30 ml · 4 week (5 days per week)As given in this study (human).

    Source sentences

    Summary
    Although there was a moderate tendency in the drug group towards loss of improvement, the differences between baseline and follow-up examination, as well as the differences between the verum and the placebo group, clearly document a sustained improvement in patients treated with Cerebrolysin in the…
    2 context sentences
    Summary · context
    The significant and clinically relevant improvements in the global rating (CGI), clinical symptomatology (SCAG), cognitive performance (ZVT-G) as primary efficacy variables
    Summary · context
    101 patients suffering from DAT were evaluated 6 months after completion of a 4 week (5 days per week) therapy with either 30 ml Cerebrolysin or placebo.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with Alzheimer's-type dementia, Cerebrolysin largely maintained SCAG improvement during follow-up compared with placebo.

    In plain wordsIn patients with dementia, Cerebrolysin largely maintained symptom improvement during follow-up compared with placebo.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseClinical symptomatology SCAG at follow-up
    Study

    n = 101

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    30 ml · 4 week (5 days per week)As given in this study (human).

    Source sentences

    Summary
    Although there was a moderate tendency in the drug group towards loss of improvement, the differences between baseline and follow-up examination, as well as the differences between the verum and the placebo group, clearly document a sustained improvement in patients treated with Cerebrolysin in the…
    2 context sentences
    Summary · context
    The significant and clinically relevant improvements in the global rating (CGI), clinical symptomatology (SCAG), cognitive performance (ZVT-G) as primary efficacy variables
    Summary · context
    101 patients suffering from DAT were evaluated 6 months after completion of a 4 week (5 days per week) therapy with either 30 ml Cerebrolysin or placebo.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with Alzheimer's-type dementia, Cerebrolysin largely maintained ZVT-G improvement during follow-up compared with placebo.

    In plain wordsIn patients with dementia, Cerebrolysin largely maintained cognitive improvement during follow-up compared with placebo.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseCognitive performance ZVT-G at follow-up
    Study

    n = 101

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    30 ml · 4 week (5 days per week)As given in this study (human).

    Source sentences

    Summary
    Although there was a moderate tendency in the drug group towards loss of improvement, the differences between baseline and follow-up examination, as well as the differences between the verum and the placebo group, clearly document a sustained improvement in patients treated with Cerebrolysin in the…
    2 context sentences
    Summary · context
    The significant and clinically relevant improvements in the global rating (CGI), clinical symptomatology (SCAG), cognitive performance (ZVT-G) as primary efficacy variables
    Summary · context
    101 patients suffering from DAT were evaluated 6 months after completion of a 4 week (5 days per week) therapy with either 30 ml Cerebrolysin or placebo.
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with Alzheimer's-type dementia, Cerebrolysin largely maintained daily activity improvement during follow-up compared with placebo.

    In plain wordsIn patients with dementia, Cerebrolysin largely maintained daily activity improvement during follow-up compared with placebo.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseActivities of daily living NAI at follow-up
    Study

    n = 101

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    30 ml · 4 week (5 days per week)As given in this study (human).

    Source sentences

    Summary
    as well as the improvements in the secondary efficacy variables activities of daily living (NAI) and wellbeing (Bf-S), achieved in the Cerebrolysin group after only 4 weeks of active therapy, were maintained to a large extent during the follow-up period.
    2 context sentences
    Summary · context
    Although there was a moderate tendency in the drug group towards loss of improvement, the differences between baseline and follow-up examination, as well as the differences between the verum and the placebo group, clearly document a sustained improvement in patients treated with Cerebrolysin in the…
    Summary · context
    101 patients suffering from DAT were evaluated 6 months after completion of a 4 week (5 days per week) therapy with either 30 ml Cerebrolysin or placebo.
  5. 05HumanNon-randomized trialEfficacy outcome

    In patients with Alzheimer's-type dementia, Cerebrolysin largely maintained wellbeing improvement during follow-up compared with placebo.

    In plain wordsIn patients with dementia, Cerebrolysin largely maintained wellbeing improvement during follow-up compared with placebo.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseWellbeing Bf-S at follow-up
    Study

    n = 101

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    30 ml · 4 week (5 days per week)As given in this study (human).

    Source sentences

    Summary
    as well as the improvements in the secondary efficacy variables activities of daily living (NAI) and wellbeing (Bf-S), achieved in the Cerebrolysin group after only 4 weeks of active therapy, were maintained to a large extent during the follow-up period.
    2 context sentences
    Summary · context
    Although there was a moderate tendency in the drug group towards loss of improvement, the differences between baseline and follow-up examination, as well as the differences between the verum and the placebo group, clearly document a sustained improvement in patients treated with Cerebrolysin in the…
    Summary · context
    101 patients suffering from DAT were evaluated 6 months after completion of a 4 week (5 days per week) therapy with either 30 ml Cerebrolysin or placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.